| http://www.w3.org/ns/prov#value | - All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the expected numbers of patients, trial sites and enrollment periods for the Phase 2 clinical trials, top-line and interim data from the trials, emricasan's potential to provide benefit to patients with cirrhosis or patients with cirrhosis and port
|
